Gliknik is focused on developing innovative biologics to address immune disorders, particularly through its lead product, GL-2045. This recombinant Fc fusion protein is designed to mimic the effects of intravenous immunoglobulin (IVIg), which is widely used in treating autoimmune diseases. GL-2045 aims to provide a safer and more effective alternative to traditional IVIg therapies by reproducing the active fraction of IVIg, specifically the Fc aggregates that have beneficial effects in treatment. The product has received Orphan Drug designation from the FDA for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and is expected to advance through clinical trials, offering a promising solution to the challenges posed by IVIg shortages and the risks associated with blood-derived products.

In addition to GL-2045, Gliknik is also developing GL-0719, another recombinant Fc fusion protein that selectively inhibits the classical and lectin complement pathways, which are implicated in various autoimmune diseases. Currently undergoing Phase 1 clinical trials, GL-0719 is designed to assess its safety and efficacy in treating conditions caused by the over-activation of these pathways. Gliknik's approach emphasizes the modulation of the immune system, leveraging the expertise of its team and advisors to create new treatment options for patients suffering from autoimmune diseases and cancers. Through these innovative therapies, Gliknik aims to significantly improve patient outcomes and quality of life.

United States

Gliknik is a privately held biopharmaceutical company working to ease human suffering by creating new therapies for people living with immune disorders.

Gliknik

Company Details